The Mushroom Was Never Just a Molecule

On April 18, 2026, the Trump administration signed an Executive Order titled "Accelerating Medical Treatments for Serious Mental Illness", setting in motion one of the most consequential restructurings of federal drug policy in a generation. The order targets compounds such as psilocybin, MDMA, and ibogaine (substances that have spent decades in Schedule I classification) and instructs the FDA Commissioner to issue National Priority Vouchers to sponsors holding Breakthrough Therapy designation. Those vouchers compress the standard FDA review window from 10 to 12 months down to as few as 60 days.

The order also expands the Right to Try Act to cover investigational psychedelics, meaning patients who have exhausted conventional options can access these compounds after Phase 1 safety trials are complete. An additional $50 million flows through the ARPA-H (Advanced Research Projects Agency for Health), structured as a federal matching fund designed to catalyze state-level clinical investment. Texas and Utah, both of which had already begun studying ibogaine and psilocybin for veteran populations, stand to benefit most directly. The Veterans Affairs agency, the FDA, and the Department of Health and Human Services are each bound by the order to sign data-sharing memoranda to close the long-standing gap between VA research and FDA approval pathways.

Internationally, the United States is arriving late but moving fast. Australia became the first country to permit psychiatrists to prescribe psilocybin and MDMA nationally under its Authorised Prescriber scheme in July 2023 and the model is now of broad clinical integration. Switzerland has allowed case-by-case medical access since 2014, and Germany launched a Compassionate Use Program in 2025. Canada relies on special access exemptions at the federal level, though Alberta has built a structured prescribing system at the provincial level. The 2026 Executive Order positions the US less as a follower of these models and more as a competitor to them, using the combined scale of the VA system and the commercial weight of FDA approval to drive rapid, evidence-based commercialization. Critics from within the academic medicine community have raised legitimate concerns that accelerated review windows may leave gaps in long-term safety data, particularly around the durability of therapeutic effects and the interplay between drug and therapist in these highly experiential endeavors.

Where the American model will face its most consequential test is not on the mainland, however. In the Pacific, Hawaiʻi, Guam, American Sāmoa, the CNMI (Commonwealth of the Northern Mariana Islands), and the Freely Associated States of Palau, FSM (Federated States of Micronesia), and the Marshall Islands carry a mental health burden that the executive order was designed precisely to address, yet these communities have been systematically excluded from the data systems that shape clinical policy. A 2024 analysis found that 60% of clinical trials leading to first-time FDA drug approvals failed to report the number of Native Hawaiian and Other Pacific Islanders (NHOPI) participants at all. Countries like the FSM and Kiribati post suicide rates approaching double the global average. Among NHPI students, 15% reported a suicide attempt in the previous twelve months, which is the highest rate of any demographic group tracked by the CDC.

The military dimension of this story is impossible to separate from the policy one. NHOPI individuals make up approximately 0.3% of the U.S. population but account for 1.3% of active-duty Navy and Air Force personnel, and an extraordinary 10.5% to 11.1% of Army Reserve members. In American Sāmoa, military service has long been an economic anchor and a marker of cultural identity. As of 2025, roughly 6.6% of the NHPI population in the United States carried veteran status. Many of those veterans return to island communities where specialized psychiatric infrastructure is thin or absent, and where existing VA outreach has historically struggled to build engagement. Trust scores for the VA among Pacific veterans under 45 sit between 83% and 86%, which is lower than among older cohorts, and lower than the national average. Psychedelic-assisted therapy, if positioned through a purely biomedical Western lens, is likely to widen that trust gap.

This is where the policy conversation must intersect with the question about cultural epistemology. Indigenous Pacific and Māori scholars have consistently argued that the clinical category of "psychedelic" is itself a Western construct that strips these substances of their ceremonial meaning. The Tū Wairua project in Aotearoa, a Māori-led Phase 1 clinical trial based at Rangiwaho Marae in Tairāwhiti, offers a model that has drawn international attention: The trial integrates mātauranga Māori (Māori knowledge systems) with rongoā Māori (traditional healing), and it secured a license to use the whole Whare Atua native mushroom species Psilocybe weraroa rather than synthetic psilocybin. The legal foundation is Te Tiriti o Waitangi, which affirms Māori rights to their taonga, including native psychoactive fungi like Whare Atua. Dosing sessions, called Nohopuku, take place within the marae where the healing process is communal, not clinical.

For NHOPI communities, the analogous model is the Ahupuaʻa cultural healing framework promoted by Papa Ola Lōkahi in Hawaiʻi, which treats inter-generational trauma and cultural reclamation as foundational to recovery rather than incidental to it. The Koa program has demonstrated that intercultural clinical work (where family members and community elders are brought into preparation phases, and integration is conducted in communal circles rather than one-on-one sessions) produces measurable gains in engagement and clinical outcomes. Adapted for psychedelic-assisted therapy, this means that dosing environments incorporate traditional music, ceremonial symbols, and place-based meaning. The therapy does not end with the session, it continues in the way the veteran's experience is interpreted within the story of their community.

The US Food and Drug Omnibus Reform Act (FDORA) now requires Phase 3 sponsors to submit Diversity Action Plans that set enrollment goals by race, ethnicity, age, and sex. For sponsors of psilocybin or MDMA therapies, excluding Pacific Islanders from those plans (given the demonstrable burden of PTSD and depression in those communities) would be a regulatory vulnerability and a scientific failure too.

The FDA's guidance on reducing participation burden specifically endorses telehealth for preparation and integration sessions, mobile health professionals for in-person dosing, and real-world data collection for remote tracking. The agency already has a physical presence in Guam, through a pilot program established in 2022, and the VA Pacific Islands Health Care System, headquartered in Honolulu, covers millions of square miles of ocean, including rural Guam and American Sāmoa. The infrastructure exists. The question is whether the political will and funding allocation will actually follow.

The $50 million ARPA-H matching fund is the point of greatest risk for the Pacific. If that capital flows primarily to large research universities in the continental United States, then territorial and COFA health departments will be shut out of the research ecosystem before it even forms. A portion of those matching funds reserved for territorial and COFA health systems is a condition of the research being scientifically valid. You cannot build a treatment protocol for a population from which you have drawn no data, can you?

The Operation Warp Speed vaccine rollout, which included COFA nations through weekly teleconferences and close federal consultation, showed that Pacific inclusion in federal health programs is possible when it is made a structural priority. Governor Lou Leon Guerrero of Guam made the governing principle explicit in her 2026 State of the Island Address: Federal plans must be made with Guam, not simply for Guam.

That principle applies with equal force to the language dimension of this rollout. Clinical trial consent forms, integration materials, community outreach, and patient education in Chamorro, Chuukese, Yapese, Pohnpeian, Kosraean, Carolinian, Marshallese, Palauan, Samoan, and Hawaiian must not be treated as translation tasks in the conventional sense. They are acts of cultural mediation that require translators who hold the linguistic competency and the epistemological literacy to carry concepts like informed consent, therapeutic set and setting, or intergenerational trauma across worldviews.

The difference between a translated document and a culturally adapted one is the difference between a patient who signs a form and one who actually understands what they are agreeing to. In a therapy where psychological safety is the therapeutic mechanism, that distinction is clinically consequential. Organizations entering this space without that kind of specialized, regionally grounded language capacity are taking on a risk they may not have quantified yet.